Live Updates > Live Update Details
2025-11-03 13:22:37
Goldman Sachs initiates coverage of Connoya with a "Buy" rating and a target price of HK$92.67. The company's first commercialized product, Stapokibatar, has been approved in mainland China for the treatment of atopic dermatitis, chronic sinusitis, and seasonal allergic rhinitis. Leveraging Stapokibatar's first-mover advantage in these areas, the bank believes the drug will provide a solid foundation for the company's valuation, with peak sales expected to exceed RMB 5 billion by 2035. Furthermore, the bank anticipates even greater growth momentum from CM512, believing it to be a better option for asthma and chronic obstructive pulmonary disease (COPD); global sales of CM512 are projected to reach US$3.3 billion before and US$694 million after the PoS phase in 2035.
